Merck & Co., Inc. (MRK): Net Income
$18.25B
Year ended 2025-12-31
$3.17B
Trailing 12 months to 2026-06-30
+7.9%
3-year compound annual growth
+20.9%
5-year compound annual growth
+15.2%
10-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.25B | +6.6% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $17.12B | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $365.00M | -97.5% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $14.52B | +11.3% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $13.05B | +84.6% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $7.07B | -28.2% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $9.84B | +58.2% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $6.22B | +159.8% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $2.39B | -38.9% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $3.92B | -11.8% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $4.44B | -62.7% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $11.92B | +170.7% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $4.40B | -28.6% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $6.17B | -1.7% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $6.27B | +628.5% | 2014-02-27, From 2011-01-01 |
| 2010-12-31 | $861.00M | -93.3% | 2013-02-28, From 2010-01-01 |
| 2009-12-31 | $12.90B | +65.2% | 2012-02-28, From 2009-01-01 |
| 2008-12-31 | $7.81B | +138.4% | 2011-02-28, From 2008-01-01 |
| 2007-12-31 | $3.28B | n/a | 2010-03-01, From 2007-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | 2025-12-31 | $18.25B | +6.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $20.64B | +94.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $7.77B | -3.2% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $4.23B | -1.2% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
| Johnson & Johnson (JNJ) | 2025-12-28 | $26.80B | +90.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.41B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.50B | +2.1% |
Compare MRK, LLY, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗